Discover how completing your trials in Canada can accelerate your early phase clinical research by six to nine weeks compared to an IND submission.
In this issue of The Altascientist, we discuss the significant advantages of conducting early phase clinical research on novel compounds in Canada versus other locations. Timely completion of necessary studies is a critical element of drug development, bringing important treatments to patients, in a safe and cost efficient way.
We cover:
- Time and cost savings with Canadian CTA
- Regulatory review process predictability
- Clinical trial participants
- Business efficiency cost savings
- Clinical trial participants
We'll also cover FAQs about the Canadian CTA including:
- Documentation
- Requirements
- Review timelines
- Product development
- CTA submissions.
Interested? Complete your details in the box to receive access.
Download Now
Asset 10: Complete Your Clinical Research 6 to 9 Weeks Faster
PDF, Size 0 kb
